Search Results - "Meadows, Kellen"

Anti-VEGF therapies in the clinic by Meadows, Kellen L, Hurwitz, Herbert I

“…The development and use of antiangiogenesis agents, particularly those targeting vascular endothelial growth factor (VEGF), has become an integral component of…”
Get full text

8-Oxoguanine-mediated transcriptional mutagenesis causes Ras activation in mammalian cells by Saxowsky, Tina T, Meadows, Kellen L, Klungland, Arne, Doetsch, Paul W

“…8-Oxoguanine (8OG) is efficiently bypassed by RNA polymerases in vitro and in bacterial cells in vivo, leading to mutant transcripts by directing incorporation…”
Get full text

A Phase I Trial of the IGF‐1R Antibody Ganitumab (AMG 479) in Combination with Everolimus (RAD001) and Panitumumab in Patients with Advanced Cancer by Vlahovic, Gordana, Meadows, Kellen L., Hatch, Ace J., Jia, Jingquan, Nixon, Andrew B., Uronis, Hope E., Morse, Michael A., Selim, M. Angelica, Crawford, Jeffrey, Riedel, Richard F., Zafar, S. Yousuf, Howard, Leigh A., O'Neill, Margot, Meadows, Jennifer J., Haley, Sherri T., Arrowood, Christy C., Rushing, Christel, Pang, Herbert, Hurwitz, Herbert I.

“…Purpose This study evaluated the maximum tolerated dose or recommended phase II dose (RPTD) and safety and tolerability of the ganitumab and everolimus doublet…”
Get full text

Treatment of palmar-plantar erythrodysesthesia (PPE) with topical sildenafil: a pilot study by Meadows, Kellen L., Rushing, Christel, Honeycutt, Wanda, Latta, Kenneth, Howard, Leigh, Arrowood, Christy A., Niedzwiecki, Donna, Hurwitz, Herbert I.

“…Purpose Palmar-plantar erythrodysesthesia (PPE) is a common chemotherapy and anti-VEGF multi-kinase inhibitor class-related toxicity that often results in…”
Get full text

A Phase II Study of Capecitabine, Oxaliplatin, and Bevacizumab in the Treatment of Metastatic Esophagogastric Adenocarcinomas by Uronis, Hope E., Bendell, Johanna C., Altomare, Ivy, Blobe, Gerard C., Hsu, S. David, Morse, Michael A., Pang, Herbert, Zafar, S. Yousuf, Conkling, Paul, Favaro, Justin, Arrowood, Christy C., Cushman, Stephanie M., Meadows, Kellen L., Brady, John C., Nixon, Andrew B., Hurwitz, Herbert I.

“…Background. Esophageal and gastric cancers often present at an advanced stage. Systemic chemotherapy is the mainstay of treatment, but survival with current…”
Get full text

Phase I study of pazopanib plus TH-302 in advanced solid tumors by Riedel, Richard F., Meadows, Kellen L., Lee, Paula H., Morse, Michael A., Uronis, Hope E., Blobe, Gerard C., George, Daniel J., Crawford, Jeffrey, Niedzwiecki, Donna, Rushing, Christel N., Arrowood, Christy C., Hurwitz, Herbert I.

“…Purpose To define the maximum tolerated dose (MTD), recommended phase II dose (RPTD), and assess safety and tolerability for the combination of pazopanib plus…”
Get full text

Dynamic Compartmentalization of Base Excision Repair Proteins in Response to Nuclear and Mitochondrial Oxidative Stress by Griffiths, Lyra M., Swartzlander, Dan, Meadows, Kellen L., Wilkinson, Keith D., Corbett, Anita H., Doetsch, Paul W.

“…Article Usage Stats Services MCB Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
Get full text

Phase I study of bevacizumab, everolimus, and panobinostat (LBH-589) in advanced solid tumors by Strickler, John H., Starodub, Alexander N., Jia, Jingquan, Meadows, Kellen L., Nixon, Andrew B., Dellinger, Andrew, Morse, Michael A., Uronis, Hope E., Marcom, P. Kelly, Zafar, S. Yousuf, Haley, Sherri T., Hurwitz, Herbert I.

“…Purpose To define the maximum tolerated dose, clinical toxicities, and pharmacodynamics of bevacizumab, everolimus, and panobinostat (LBH-589) when…”
Get full text

A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors by Vlahovic, Gordana, Meadows, Kellen L., Uronis, Hope E., Morse, Michael A., Blobe, Gerard C., Riedel, Richard F., Zafar, S. Yousuf, Alvarez-Secord, Angeles, Gockerman, Jon, Starodub, Alexander N., Ready, Neal E., Anderson, Elizabeth L., Bendell, Johanna C., Hurwitz, Herbert I.

“…Purpose Preclinical data suggest concurrent inhibition of VEGF, mTOR and EGFR pathways may augment antitumor and antiangiogenic effects compared to inhibition…”
Get full text

Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer by Strickler, John H., McCall, Shannon, Nixon, Andrew B., Brady, John C., Pang, Herbert, Rushing, Christel, Cohn, Allen, Starodub, Alexander, Arrowood, Christy, Haley, Sherri, Meadows, Kellen L., Morse, Michael A., Uronis, Hope E., Blobe, Gerard C., Hsu, S. David, Zafar, S. Yousuf, Hurwitz, Herbert I.

“…Summary Purpose Dasatinib inhibits src family kinases and has anti-angiogenic properties. We conducted a phase I study of dasatinib, capecitabine, oxaliplatin,…”
Get full text

phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE) by Bullock, Karen E, Petros, William P, Younis, Islam, Uronis, Hope E, Morse, Michael A, Blobe, Gerard C, Yousuf Zafar, S, Gockerman, Jon P, Lager, Joanne J, Truax, Roxanne, Meadows, Kellen L, Howard, Leigh A, O'Neill, Margot M, Broadwater, Gloria, Hurwitz, Herbert I, Bendell, Johanna C

“…Purpose VEGF, mTOR, and EGFR inhibitors have demonstrated anti-tumor and anti-angiogenic effects alone and in combination with each other. This study evaluated…”
Get full text

Phase I and pharmacokinetic study of lonafarnib, SCH 66336, using a 2-week on, 2-week off schedule in patients with advanced solid tumors by Castaneda, Carlos, Meadows, Kellen L, Truax, Roxanne, Morse, Michael A, Kaufmann, Scott H, Petros, William P, Zhu, Yali, Statkevich, Paul, Cutler, David L, Hurwitz, Herbert I

“…Purpose This phase I study was performed to determine the safety profile, maximum tolerated dose (MTD) and biological activity of lonafarnib (SCH 66336)…”
Get full text

Phase I study of bevacizumab, everolimus, and panobinostat (LBH-589) in advanced solid tumors by STRICKLER, John H, STARODUB, Alexander N, HALEY, Sherri T, HURWITZ, Herbert I, JINGQUAN JIA, MEADOWS, Kellen L, NIXON, Andrew B, DELLINGER, Andrew, MORSE, Michael A, URONIS, Hope E, KELLY MARCOM, P, YOUSUF ZAFAR, S

Get full text

Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors by Rangwala, Fatima, Bendell, Johanna C., Kozloff, Mark F., Arrowood, Christy C., Dellinger, Andrew, Meadows, Jennifer, Tourt-Uhlig, Sandra, Murphy, Jennifer, Meadows, Kellen L., Starr, Aijing, Broderick, Samuel, Brady, John C., Cushman, Stephanie M., Morse, Michael A., Uronis, Hope E., Hsu, S. David, Zafar, S. Yousuf, Wallace, James, Starodub, Alexander N., Strickler, John H., Pang, Herbert, Nixon, Andrew B., Hurwitz, Herbert I.

“…Summary Purpose To define maximum tolerated dose (MTD), toxicities, and pharmacodynamics of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced…”
Get full text

A Phase I Multicenter Study of Continuous Oral Administration of Lonafarnib (SCH 66336) and Intravenous Gemcitabine in Patients With Advanced Cancer by Wong, Nan Soon, Meadows, Kellen L., Rosen, Lee S., Adjei, Alex A., Kaufmann, Scott H., Morse, Michael A., Petros, William P., Zhu, Yali, Statkevich, Paul, Cutler, David L., Meyers, Michael L., Hurwitz, Herbert I.

“…We conducted a phase I study to assess safety, pharmacokinetics, pharmacodynamics, and activity of lonafarnib plus gemcitabine. Subjects received oral…”
Get full text

A phase I study of ABT‐510 plus bevacizumab in advanced solid tumors by Uronis, Hope E., Cushman, Stephanie M., Bendell, Johanna C., Blobe, Gerard C., Morse, Michael A., Nixon, Andrew B., Dellinger, Andrew, Starr, Mark D., Li, Haiyan, Meadows, Kellen, Gockerman, Jon, Pang, Herbert, Hurwitz, Herbert I.

“…Targeting multiple regulators of tumor angiogenesis have the potential to improve treatment efficacy. Bevacizumab is a monoclonal antibody directed against…”
Get full text

Characterization of AP lyase activities of Saccharomyces cerevisiae Ntg1p and Ntg2p: implications for biological function by Meadows, Kellen L., Song, Binwei, Doetsch, Paul W.

“…Saccharomyces cerevisiae possesses two Escherichia coli endonuclease III homologs, NTG1 and NTG2, whose gene products function in the base excision repair…”
Get full text

Genome-wide analysis of loss of heterozygosity and copy number amplification in uterine leiomyomas using the 100K single nucleotide polymorphism array by Meadows, Kellen L., Andrews, Danica M.K., Xu, Zongli, Carswell, Gleta K., Laughlin, Shannon K., Baird, Donna D., Taylor, Jack A.

“…Uterine leiomyomas (fibroids) are benign smooth muscle tumors commonly found among reproductive-aged women. Though benign, these tumors are the leading…”
Get full text

Phase I Dose Escalation Study of Gemcitabine plus Irinotecan in Advanced Solid Tumors by Dugan, Elizabeth, Truax, Roxanne, Meadows, Kellen L, Blobe, Gerald C, Morse, Michael A, Fernando, Nishan H, Gockerman, Jon P, Petros, William P, Hurwitz, Herbert I

“…Aim: To determine the maximally tolerated dose (MTD), recommended phase II dose (RPTD) and toxicity profile of gemcitabine plus irinotecan combination…”
Get full text

A Phase I Dose-Escalation Study of Imatinib Mesylate (Gleevec/STI571) plus Capecitabine (Xeloda) in Advanced Solid Tumors by DUGAN, Elizabeth, TRUAX, Roxanne, MEADOWS, Kellen L, NIXON, Andrew B, PETROS, William P, FAVARO, Justin, FERNANDO, Nishan H, MORSE, Michael A, BLOBE, Gerard C, HURWITZ, Herbert I

“…The aim of this study was to determine the maximally tolerated dose, recommended phase II dose and toxicity profile of capecitabine plus imatinib mesylate…”
Get full text